Karen Walton-Bowen Joins Abt Bio-Pharma Solutions, Inc., as Senior Director, ...( CAMBRIDGE Mass. Oct. 22 /- Karen ...)

CAMBRIDGE, Mass., Oct. 22 /PRNewswire/ -- Karen Walton-Bowen, M.Sc., C.Stat, a biostatistician with more than 20 years experience in the pharmaceutical and biotechnology industries, has joined Abt Bio-Pharma Solutions, Inc. (ABS), as Senior Director, Biometrics. An expert in clinical trials and regulatory submissions in all phases of clinical development across multiple therapeutic areas, Ms. Walton-Bowen's experience encompasses clinical operations, data management, programming, statistical support, and medical writing, both in the U.S. and in Europe. In addition to leading ABS' full service Biometrics team, she will work one-on-one with sponsors to provide sophisticated biostatistics and medical writing consulting services for registries and late-phase clinical trials.

"Karen's strong technical and project management skills will make her a 'go to' resource for our small- to medium-size clients who wish to extend their capabilities with direct access to an hands-on expert with broad and deep therapeutic area experience," said Dr. Kay Larholt, Vice President of Biometrics & Clinical Operations. "We also expect Karen to add value and strengthen our already accomplished Biometrics team as it continues to support all our clinical projects, including clinical trials and registries."

Prior to joining ABS, Ms. Walton-Bowen was most recently Senior Director of Clinical Operations, Biostatistical Analysis, and Reporting at Critical Therapeutics, Inc. Previously, she spent four years at Genzyme Corporation, where she led the Biometrics team in a successful BLA submission and FDA Advisory Panel approval of a drug for a rare life-threatening disease in children. Ms. Walton-Bowen also spent many years at Astra (in the US and Sweden) as a biostatistician working on different compounds in the respiratory business unit. During that time she submitted numerous NDAs and represented the company at FDA meetings and Advisory Panels.

Ms. Walton-Bowen was awar
'/>"/>